BioCentury | Sep 22, 2014
Finance

Caught short

...$47.5 $36,587 Synageva BioPharma Corp. (NASDAQ:GEVA) 1/5/12 $90.0 $128,353 Vivus Inc. (NASDAQ:VVUS) 2/29/12 $202.5 $49,037 BG Medicine Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...NASDAQ:EXAS) 4/4/14 $146.6 $1,055.2 $1,410.3 34% Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) 4/4/14 $192.0 $6,438.3 $4,989.9 -22% BG Medicine Inc....
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

To capitalize on the full range of possible chromatin targets in and beyond oncology, industry and academia will need to delve deeper into how chromatin regulation is altered in disease, create tools that can reliably...
BioCentury | Apr 7, 2014
Financial News

BG Medicine completes follow-on

BG Medicine Inc. (NASDAQ: BGMD), Waltham, Mass. Business: Diagnostic Date completed: 4/3/14 Type: Follow-on Raised: $10 million Shares: 6.5 million Price: $1.55 Shares after offering: 34.4 million Underwriter: Lazard Overallotment: 967,800 WIR Staff Diagnostic...
BioCentury | Mar 17, 2014
Financial News

BG Medicine financial update

...that it regained compliance with the $35 million minimum market value requirement for continued listing. BG Medicine Inc....
BioCentury | Dec 16, 2013
Clinical News

BGM Galectin-3 test regulatory update

...soluble beta-galactoside-binding lectin associated with the formation of cardiac fibrosis, in human plasma or serum. BG Medicine Inc....
BioCentury | Oct 14, 2013
Clinical News

BGM Galectin-3 test regulatory update

...clinical laboratory fee schedule for 2014 and to a 2% sequestration applicable to Medicare services. BG Medicine...
...soluble beta-galactoside-binding lectin associated with the formation of cardiac fibrosis, in human plasma or serum. BG Medicine Inc....
BioCentury | Oct 14, 2013
Company News

Acorda management update

...N.Y. Business: Neurology, Musculoskeletal, Autoimmune Hired: Michael Rogers as CFO, formerly EVP and CFO of BG Medicine Inc....
BioCentury | Oct 7, 2013
Financial News

BG Medicine financial update

...price requirement for continued listing. The company has until March 24, 2014, to regain compliance. BG Medicine Inc....
BioCentury | May 13, 2013
Company News

BG Medicine management update

BG Medicine Inc. (NASDAQ:BGMD), Waltham, Mass. Business: Diagnostic, Proteomics, Supply/Service Hired: Paul Sohmer as president, CEO and a director, formerly president and CEO of ViraCor-IBT Laboratories Inc. ; he replaces Eric Bouvier WIR Staff Diagnostic...
Items per page:
1 - 10 of 162
BioCentury | Sep 22, 2014
Finance

Caught short

...$47.5 $36,587 Synageva BioPharma Corp. (NASDAQ:GEVA) 1/5/12 $90.0 $128,353 Vivus Inc. (NASDAQ:VVUS) 2/29/12 $202.5 $49,037 BG Medicine Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...NASDAQ:EXAS) 4/4/14 $146.6 $1,055.2 $1,410.3 34% Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) 4/4/14 $192.0 $6,438.3 $4,989.9 -22% BG Medicine Inc....
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

To capitalize on the full range of possible chromatin targets in and beyond oncology, industry and academia will need to delve deeper into how chromatin regulation is altered in disease, create tools that can reliably...
BioCentury | Apr 7, 2014
Financial News

BG Medicine completes follow-on

BG Medicine Inc. (NASDAQ: BGMD), Waltham, Mass. Business: Diagnostic Date completed: 4/3/14 Type: Follow-on Raised: $10 million Shares: 6.5 million Price: $1.55 Shares after offering: 34.4 million Underwriter: Lazard Overallotment: 967,800 WIR Staff Diagnostic...
BioCentury | Mar 17, 2014
Financial News

BG Medicine financial update

...that it regained compliance with the $35 million minimum market value requirement for continued listing. BG Medicine Inc....
BioCentury | Dec 16, 2013
Clinical News

BGM Galectin-3 test regulatory update

...soluble beta-galactoside-binding lectin associated with the formation of cardiac fibrosis, in human plasma or serum. BG Medicine Inc....
BioCentury | Oct 14, 2013
Clinical News

BGM Galectin-3 test regulatory update

...clinical laboratory fee schedule for 2014 and to a 2% sequestration applicable to Medicare services. BG Medicine...
...soluble beta-galactoside-binding lectin associated with the formation of cardiac fibrosis, in human plasma or serum. BG Medicine Inc....
BioCentury | Oct 14, 2013
Company News

Acorda management update

...N.Y. Business: Neurology, Musculoskeletal, Autoimmune Hired: Michael Rogers as CFO, formerly EVP and CFO of BG Medicine Inc....
BioCentury | Oct 7, 2013
Financial News

BG Medicine financial update

...price requirement for continued listing. The company has until March 24, 2014, to regain compliance. BG Medicine Inc....
BioCentury | May 13, 2013
Company News

BG Medicine management update

BG Medicine Inc. (NASDAQ:BGMD), Waltham, Mass. Business: Diagnostic, Proteomics, Supply/Service Hired: Paul Sohmer as president, CEO and a director, formerly president and CEO of ViraCor-IBT Laboratories Inc. ; he replaces Eric Bouvier WIR Staff Diagnostic...
Items per page:
1 - 10 of 162